REG - Oxford Cannabinoid - New Broker and Investor Presentation

Oxford Cannabinoid Technologies HoldingsAnnouncement

16/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220516:nRSP5218La&default-theme=true

RNS Number : 5218L  Oxford Cannabinoid Tech.Holdings  16 May 2022

 

Oxford Cannabinoid Technologies Holdings plc

("OCTP" or "the Company")

 

Appointment of Axis Capital Markets as Corporate Broker

&

Notice of Investor Meet Company Live Q&A Session

 

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company
developing prescription cannabinoid medicines targeting the US$ multi-billion
pain market, is pleased to announce the appointment of Axis Capital Markets
Limited ("AxCap") as the Company's corporate broker with immediate effect
(www.axcap247.com (http://www.axcap247.com) ).

 

AxCap will work alongside OCTP's existing financial adviser, Cairn Financial
Advisers LLP.

 

Investor Meet Company Q&A Session, 4:30 p.m., 30 May 2022

The Company is also pleased to announce that it will be hosting a live online
Q&A session via the Investor Meet Company platform at 4:30 p.m. BST on 30
May 2022, which is open to all existing and potential shareholders.

 

Questions can be submitted pre-event via the 'Investor Meet Company' dashboard
up until 9:00 a.m. on Friday 27 May 2022 or at any time during the live
presentation. Investors can sign up to Investor Meet Company for free
via: https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor
(https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor%20%0d)

 

Investors who already follow OCTP on the Investor Meet Company platform will
automatically receive an invitation to the event. The Company will also use
this opportunity to respond to questions already received.

 

The Directors of the Company accept responsibility for the content of this
announcement.

 

Enquiries:

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820

 Dr John Lucas (CEO)                           john@oxcantech.com (mailto:john@oxcantech.com)

 Clarissa Sowemimo-Coker (COO)                 clarissa@oxcantech.com

 Cairn Financial Advisers LLP

 Emily Staples                                 +44 (0)20 7213 0897

 Jo Turner                                     +44 (0)20 7213 0885

 Axis Capital Markets Limited                  +44 (0)20 3026 0320

 Kamran Hussain

 Richard Hutchison

 Walbrook PR Limited                           +44 (0)20 7933 8780

 Paul Vann/Nick Rome                           +44 (0)7768 807631

                                               oxcantech@walbrookpr.com (mailto:oxcantech@walbrookpr.com)

+1 (475) 455 9403
 Harbor Access LLC

                                             Richard.Leighton@HarborAccessllc.com
 Richard Leighton/Jonathan Paterson

About Oxford Cannabinoid Technologies Holdings plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company
of Oxford Cannabinoid Technologies Ltd ("OCT"), a pharmaceutical company
developing prescription cannabinoid medicines for approval by key medicines
regulatory agencies worldwide and targeting the U$ multi-billion pain
market (together the "Group"). Cannabinoids are compounds found in the
cannabis plant that have been shown to have a range of therapeutic effects on
the body, including pain relief. The Group has a clearly defined path to
commercialisation, revenues and growth. The Group is developing drug
candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA)
that will enable medical professionals to prescribe them with confidence.

 

The Group's portfolio aims to balance risk, value and time to market, whilst
ensuring market exclusivity around all its key activities. The Group's lead
compound, OCT461201, is a highly potent and selective CB2 agonist and is being
developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical
testing and development with clinical trials scheduled for Q1 2023. The
Group's product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of rare
diseases and includes chemically modified phytocannabinoids with improved
drug-like characteristics and a proprietary library of cannabinoids.

 

OCTP operates a partnership model with external academic and commercial
partners.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFVDEAIVLIF